One study evaluating ADAM17 as a potential blood biomarker for ovarian cancer showed that ADAM17 levels are significantly higher in culture medium supernatants of cultured ovarian cancer cell lines and also in the serum and ascites of patients with ovarian cancer, compared with controls (94). This evidence concerns the gene ADAM17 and ovarian cancer.